Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis

BACKGROUND: The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG(4) for improved pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Frank, Mansfield, John C, Lekkerkerker, Annemarie N, Wang, Yehong, Keir, Mary, Dash, Ajit, Butcher, Brandon, Harder, Brandon, Orozco, Luz D, Mar, Jordan S, Chen, Hao, Rothenberg, Michael E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359578/
https://www.ncbi.nlm.nih.gov/pubmed/36732049
http://dx.doi.org/10.1136/gutjnl-2022-328387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359578/
https://www.ncbi.nlm.nih.gov/pubmed/36732049
http://dx.doi.org/10.1136/gutjnl-2022-328387

Ejemplares similares